Clinical Trials Logo

Conjunctivitis clinical trials

View clinical trials related to Conjunctivitis.

Filter by:

NCT ID: NCT00347932 Completed - Clinical trials for Acute Bacterial Conjunctivitis

A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.

Start date: June 2006
Phase: Phase 3
Study type: Interventional

Evaluation of the clinical and microbial efficacy of 0.6% ISV-403, compared to vehicle in the treatment of bacterial conjunctivitis.

NCT ID: NCT00332293 Completed - Clinical trials for Bacterial Conjunctivitis

AL-15469A for the Treatment of Bacterial Conjunctivitis

Start date: May 2006
Phase: Phase 3
Study type: Interventional

The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.

NCT ID: NCT00331916 Completed - Clinical trials for Bacterial Conjunctivitis

AL-15469A for the Treatment of Bacterial Conjunctivitis

Start date: November 2005
Phase: Phase 3
Study type: Interventional

The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.

NCT ID: NCT00331500 Completed - Clinical trials for Allergic Conjunctivitis

Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis

Start date: April 18, 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate that Olopatadine 0.2% is superior to vehicle in the treatment of the signs and symptoms associated with allergic conjunctivitis or rhinoconjunctivitis.

NCT ID: NCT00328653 Completed - Clinical trials for Conjunctivitis, Vernal

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)

Start date: May 2006
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective of this study is: - To assess the efficacy of Nova22007, a cyclosporine A (CsA), 0.05% and 0.1% versus vehicle in patients with vernal keratoconjunctivitis (VKC) after a 4-week treatment period. The secondary objectives of this study are: - To compare the safety and ocular tolerance of Nova22007 0.05% and 0.1%; - To assess the long term safety and ocular tolerance of Nova22007 0.05% and 0.1%; and - To assess the decrease in frequency of concomitant artificial tears use.

NCT ID: NCT00312338 Completed - Clinical trials for Bacterial Conjunctivitis

Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora

Start date: June 2006
Phase: Phase 4
Study type: Interventional

Topical Treatment of Bacterial Conjunctivitis and its Effect on Microbial Flora

NCT ID: NCT00311844 Completed - Clinical trials for Conjunctivitis, Allergic

A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209)

Start date: March 1, 2005
Phase: Phase 4
Study type: Interventional

This study was a double-blind, placebo-controlled, cross-over, single-center study of desloratadine 5 mg or placebo in subjects 18 years of age or older with a history of seasonal allergic rhinoconjunctivitis. This study was performed to examine the effects of desloratadine compared with placebo, on the signs and symptoms of allergic conjunctivitis induced by direct conjunctival challenges with a previously identified sensitizing antigen, in the eyes of a subject known to be sensitive to the antigen.

NCT ID: NCT00266734 Completed - Clinical trials for Adenoviral Conjunctivitis

Evaluation of a Rapid Screening Test for Detection of Adenovirus in Tears

Start date: December 2004
Phase: N/A
Study type: Interventional

To compare the efficacy of a recently FDA approved point of care diagnostic test, the RPS Adeno Detector (Rapid Pathogen Screening, Inc.; South Williamsport, PA), against cell culture for detecting adenoviral conjunctivitis

NCT ID: NCT00244543 Completed - Clinical trials for Allergic Conjunctivitis

Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis

Start date: October 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to establish the efficacy of R89674 0.25% ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allergic conjunctivitis

NCT ID: NCT00241319 Completed - Clinical trials for Allergic Conjunctivitis

Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis

Start date: October 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to establish the efficacy of R89674 0.25% ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allergic conjunctivitis